$612 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 59 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 186.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $71,994,000 | +131.2% | 4,260,000 | +9.5% | 11.76% | +100.1% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $54,791,000 | +11.4% | 1,115,000 | +2.6% | 8.95% | -3.6% |
| XBI | Buy | SPDR SERIES TRUSTput | $43,866,000 | +47.7% | 500,000 | +42.9% | 7.16% | +27.7% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $35,578,000 | +67.3% | 544,000 | +2.4% | 5.81% | +44.7% |
| ARGX | Buy | ARGENX SEsponsored adr | $32,483,000 | +59.3% | 403,821 | +25.0% | 5.30% | +37.8% |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $29,792,000 | +385.4% | 1,154,722 | +156.6% | 4.87% | +319.8% |
| KDMN | Buy | KADMON HLDGS INC | $25,288,000 | +42.1% | 5,950,000 | +21.1% | 4.13% | +23.0% |
| VCYT | Buy | VERACYTE INC | $18,448,000 | -14.3% | 3,318,000 | +0.7% | 3.01% | -25.8% |
| CEMI | Buy | CHEMBIO DIAGNOSTICS INC | $16,053,000 | +13.7% | 2,006,667 | +16.6% | 2.62% | -1.6% |
| QQQ | New | POWERSHARES QQQ TRUSTput | $13,612,000 | – | 85,000 | +100.0% | 2.22% | – |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $12,706,000 | – | 1,762,206 | +100.0% | 2.08% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INCcall | $7,617,000 | – | 155,000 | +100.0% | 1.24% | – |
| AVXS | Buy | AVEXIS INC | $7,415,000 | +26.7% | 60,000 | +13.4% | 1.21% | +9.6% |
| TNDM | New | TANDEM DIABETES CARE INC | $6,678,000 | – | 1,346,360 | +100.0% | 1.09% | – |
| CASM | Buy | CAS MED SYS INC | $6,573,000 | +65.4% | 5,216,998 | +1.1% | 1.07% | +43.2% |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $6,563,000 | – | 350,000 | +100.0% | 1.07% | – |
| LLY | New | LILLY ELI & COput | $5,803,000 | – | 75,000 | +100.0% | 0.95% | – |
| EEM | New | ISHARES TRput | $4,828,000 | – | 100,000 | +100.0% | 0.79% | – |
| CUTR | New | CUTERA INC | $3,518,000 | – | 70,000 | +100.0% | 0.58% | – |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INCcall | $3,436,000 | +3804.5% | 203,300 | +1748.2% | 0.56% | +3200.0% |
| ARMO | New | ARMO BIOSCIENCES INC | $2,993,000 | – | 80,000 | +100.0% | 0.49% | – |
| New | INOTEK PHARMACEUTICALS CORPnote 5.750% 8/0 | $2,871,000 | – | 3,000,000 | +100.0% | 0.47% | – | |
| UTHR | New | UNITED THERAPEUTICS CORP DELput | $2,809,000 | – | 25,000 | +100.0% | 0.46% | – |
| VIVE | Buy | VIVEVE MED INC | $2,508,000 | +16.4% | 685,215 | +58.1% | 0.41% | +0.7% |
| EDIT | Buy | EDITAS MEDICINE INCput | $1,824,000 | +48.4% | 55,000 | +37.5% | 0.30% | +28.4% |
| AERI | New | AERIE PHARMACEUTICALS INCcall | $1,628,000 | – | 30,000 | +100.0% | 0.27% | – |
| NTLA | New | INTELLIA THERAPEUTICS INCput | $1,582,000 | – | 75,000 | +100.0% | 0.26% | – |
| FIXX | New | HOMOLOGY MEDICINES INC | $1,477,000 | – | 79,000 | +100.0% | 0.24% | – |
| TWTR | New | TWITTER INCcall | $1,451,000 | – | 50,000 | +100.0% | 0.24% | – |
| RARX | New | RA PHARMACEUTICALS INC | $1,434,000 | – | 270,000 | +100.0% | 0.23% | – |
| TSRO | New | TESARO INCcall | $1,429,000 | – | 25,000 | +100.0% | 0.23% | – |
| BEAT | New | BIOTELEMETRY INC | $1,242,000 | – | 40,000 | +100.0% | 0.20% | – |
| AXDX | New | ACCELERATE DIAGNOSTICS INCcall | $1,143,000 | – | 50,000 | +100.0% | 0.19% | – |
| AMPE | New | AMPIO PHARMACEUTICALS INCput | $1,105,000 | – | 325,000 | +100.0% | 0.18% | – |
| SGMO | New | SANGAMO THERAPEUTICS INCput | $950,000 | – | 50,000 | +100.0% | 0.16% | – |
| NVTRQ | New | NUVECTRA CORP | $869,000 | – | 66,724 | +100.0% | 0.14% | – |
| ANIP | New | ANI PHARMACEUTICALS INCput | $833,000 | – | 14,300 | +100.0% | 0.14% | – |
| TWTR | New | TWITTER INCput | $725,000 | – | 25,000 | +100.0% | 0.12% | – |
| AERI | New | AERIE PHARMACEUTICALS INCput | $543,000 | – | 10,000 | +100.0% | 0.09% | – |
| CRSP | New | CRISPR THERAPEUTICS AGput | $457,000 | – | 10,000 | +100.0% | 0.08% | – |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDput | $427,000 | – | 25,000 | +100.0% | 0.07% | – |
| ENDP | New | ENDO INTL PLCput | $356,000 | – | 60,000 | +100.0% | 0.06% | – |
| TRXC | Buy | TRANSENTERIX INCput | $307,000 | +51.2% | 180,000 | +71.4% | 0.05% | +31.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.